Article - 19/05/2014 Alcoholism: the molecular basis of addiction and deprivation Scientists at the Central Institute of Mental Health in Mannheim use rats and mice to study the genetic basis and neurobiological mechanisms of alcohol addiction, the changes that occur during alcohol deprivation and the factors that favour a relapse. In translational research, the results from animal experiments are reviewed using alcohol-dependent patients in order to turn them quickly into preventive strategies and therapies.https://www.gesundheitsindustrie-bw.de/en/article/news/alcoholism-the-molecular-basis-of-addiction-and-deprivation
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Dossier - 31/03/2014 Peptides – diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Article - 10/01/2014 HybridKnife – an instrument for future endoscopy Endoscopic and minimally invasive keyhole surgery is increasingly replacing open surgery. For many years now, patients have reaped the benefits of such treatment techniques, which are less stressful than open surgery and usually leave no scarring. People can leave hospital just a few days after treatment, which also contributes to cost savings in healthcare. Endoscopic submucosal dissection (ESD) is a new technique that enables the endoscopic…https://www.gesundheitsindustrie-bw.de/en/article/news/hybridknife-an-instrument-for-future-endoscopy
Article - 09/12/2013 KVART – a hospital bed with built-in intelligence Exercise is the best medicine! this was the maxim adopted by Dr. Clemens Gutknecht and Dr. Josef Schönberger when they were investigating the treatment remobilisation and care of bedridden patients. The findings of the two experienced neurologists led to the development of a concept for an intelligent hospital bed. Based on a patented technology and quantitative market potential estimates Gutknecht and Schönberger have established KVART GmbH in…https://www.gesundheitsindustrie-bw.de/en/article/news/kvart-a-hospital-bed-with-built-in-intelligence
Dossier - 15/10/2013 Adult stem cells – hope for regenerative therapies Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/adult-stem-cells-hope-for-regenerative-therapies
Article - 30/09/2013 CureVac GmbH: RNA-based vaccines and immunotherapies CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
Press release - 05/08/2013 greenovation Biotech GmbH – production of therapeutic proteins in moss Plants can be genetically modified in a way that enables them to produce pharmaceutically active proteins for various indications. The small moss Physcomitrella patens is able to produce more complex molecules than bacteria. Moreover, moss is less expensive to grow and less susceptible to pathogenic contaminants than Chinese hamster ovary (CHO) cells. greenovation Biotech GmbH, which has its headquarters in Heilbronn and a branch in Freiburg,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/greenovation-biotech-gmbh-production-of-therapeutic-proteins-in-moss
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Prior to approval of a new pharmaceutical several hurdles such as preclinical and clinical studies need to be cleared. Clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials
Dossier - 15/04/2013 Bioactive plant foods – more than just filling The increasing demand for functional foods clearly shows that the role of food is no longer just to meet an essential need. Food that offers additional nutritional benefits is becoming increasingly important for example food that is able to prevent or treat diseases. This kind of food is therefore interesting for consumers the food industry and the healthcare sector alike. Products based on plant raw materials are particularly in demand due to…https://www.gesundheitsindustrie-bw.de/en/article/dossier/bioactive-plant-foods-more-than-just-filling
Article - 08/04/2013 Top position for German placebo research Placebo research at Tübingen University is part of a German network that is a world leader in the field. One of the research priorities relates to the perception of pain and the underlying neurobiological mechanisms. https://www.gesundheitsindustrie-bw.de/en/article/news/top-position-for-german-placebo-research
Dossier - 01/04/2013 Retroviruses: from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Article - 11/03/2013 PHAST GmbH: firm focus on growth strategy Since August last year, PHAST Development GmbH & Co. KG has been bringing a breath of fresh air to the old research campus of the pharmaceutical company Takeda (formerly Nycomed) in Konstanz. The pharmaceutical company, with its roots in the city of Homburg, Germany, is a specialist in innovative methods for testing the quality of medicines. Amongst other things, PHAST develops test methods that enable the optimisation of drug release. A…https://www.gesundheitsindustrie-bw.de/en/article/news/phast-gmbh-firm-focus-on-growth-strategy
Article - 25/02/2013 Molecular monitoring of premature infants Premature births are not uncommon in Germany where around seven percent of newborns are born before week 37 of pregnancy. The WHO estimates that the numbers of preterm births are growing due to the increasing age of mothers. Doctors caring for the tiny patients are faced with a dilemma because regular blood samples required for the clinical monitoring of important blood parameters cannot be taken due to the infants low body volume.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-monitoring-of-premature-infants
Article - 14/01/2013 Boehringer takes a deep breath: a look into the company’s respiratory R&D pipeline At its 3rd International Research & Development (R&D) press conference, Boehringer Ingelheim gave journalists insights into its R&D pipeline. Around 200 scientists at the company’s site in Biberach are investigating new treatment options for patients with COPD (chronic obstructive pulmonary disease), asthma, idiopathic lung fibrosis, lung cancer and other respiratory diseases. In addition, the researchers are also focusing on the…https://www.gesundheitsindustrie-bw.de/en/article/news/boehringer-takes-a-deep-breath-a-look-into-the-company-s-respiratory-r-d-pipeline
Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
Press release - 17/12/2012 Curetis AG initiates clinical trial in the U.S. towards FDA clearance Curetis AG announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more than 2,000 hospitalized patients suspected to have a lower respiratory tract infection and several…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-initiates-clinical-trial-in-the-u-s-towards-fda-clearance
Article - 03/12/2012 Targeted therapeutic approaches that revolutionise melanoma treatment Melanoma is difficult to treat once it has spread from the skin to other parts of the body. Classical chemotherapy is often ineffective and the majority of patients die within a few months after diagnosis. However, the biggest breakthrough in around 30 years has now been achieved with the development of kinase inhibitors that directly interfere with the cancer cells’ molecular signalling pathways. Clinical research into the application of kinase…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-therapeutic-approaches-that-revolutionise-melanoma-treatment
Press release - 12/11/2012 immatics appoints Peter Chambré as Chairman immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
Press release - 09/11/2012 Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch” Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-s-apocept-for-glioblastoma-multiforme-named-one-of-top-10-projects-to-watch
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Article - 22/10/2012 syneed imaging: precise visualisation of functional tissue properties Functional medical imaging modalities are of great significance in modern medical diagnostics. Existing ways of diagnosing diseases are now being expanded with the arrival of the innovative parameter imaging method. syneed imaging uses proprietary highly sensitive software for the analysis of dynamic image data. This software complements standard methods such as computed tomography and magnetic resonance imaging and increases the significance of…https://www.gesundheitsindustrie-bw.de/en/article/news/syneed-imaging-precise-visualisation-of-functional-tissue-properties
Article - 10/09/2012 Jan Wehkamp to investigate the causes of chronic inflammatory bowel diseases It takes a great deal of courage to question a common scientific doctrine especially for scientists at the very beginning of their careers. But around ten years ago Dr. Jan Wehkamp did not shy away from doing just that and as a result he and his scientific partner Professor Dr. Eduard Stange came up with a new explanation for the pathogenesis of chronic inflammatory bowel diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/jan-wehkamp-to-investigate-the-causes-of-chronic-inflammatory-bowel-diseases
Press release - 08/08/2012 Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine